Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Duchenne Muscular Dystrophy Cardiomyopathy Clear all

Conditions: DMD-Associated Dilated Cardiomyopathy
Interventions: SRD-001; Genetic
Lead sponsor: Sardocor Corp.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio

Conditions: Duchenne Muscular Dystrophy
Interventions: wearable technology; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 10 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions: Hyperpolarized 13C-Pyruvate; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Duchenne Muscular Dystrophy
Interventions: Allogeneic Cardiosphere-Derived Cells (CAP-1002); Biological
Lead sponsor: Capricor Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Gainesville, Florida • Cincinnati, Ohio

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: SGLT-2 inhibitor, SGLT2 inhibitor; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 8 Years to 18 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions: Not listed
Lead sponsor: xCures; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Altos, California

Conditions: Duchenne Muscular Dystrophy
Interventions: eplerenone, placebo; Drug
Lead sponsor: Subha Raman; Other
Eligibility: 7 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Cincinnati, Ohio • Columbus, Ohio

Conditions: Duchenne Muscular Dystrophy (DMD), Cardiomyopathy
Interventions: Losartan, Lisinopril; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Davis, California • Kansas City, Kansas • Boston, Massachusetts + 3 more

Conditions: Duchenne Muscular Dystrophy, Cardiomyopathy
Interventions: Allogeneic Cardiosphere-Derived Cells (CAP-1002); Drug
Lead sponsor: Capricor Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • Gainesville, Florida • Cincinnati, Ohio

Conditions: Duchenne Muscular Dystrophy
Interventions: wearable technology; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 10 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Duchenne Muscular Dystrophy (DMD), Cardiomyopathy, Becker Muscular Dystrophy, Carrier of Duchenne Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Sacramento, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more

Conditions: Inherited Cardiac Arrythmias, Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Early Repolarization Syndrome (ERS), Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Normal Control Subjects
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Duchenne Muscular Dystrophy
Interventions: (+)- Epicatechin; Drug
Lead sponsor: Craig McDonald, MD; Other
Eligibility: 8 Years to 17 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated
Interventions: Ifetroban, Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 7 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 7 more

Search by objective public record fields.

Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim

UTSW HP [13-C] Pyruvate Injection in HCM

Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy

Cardiomyopathy in DMD: Lisinopril vs. Losartan

HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)

Wearable Technology to Evaluate Hyperglycemia and HRV in DMD

Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy